Literature DB >> 27032498

A preventive immunization approach against insect bite hypersensitivity: Intralymphatic injection with recombinant allergens in Alum or Alum and monophosphoryl lipid A.

Sigridur Jonsdottir1, Vilhjalmur Svansson2, Sara Bjork Stefansdottir2, Gertraud Schüpbach3, Claudio Rhyner4, Eliane Marti3, Sigurbjorg Torsteinsdottir2.   

Abstract

Insect bite hypersensitivity (IBH) is an IgE-mediated dermatitis of horses caused by bites of Culicoides insects, not indigenous to Iceland. Horses born in Iceland and exported to Culicoides-rich areas are frequently affected with IBH. The aims of the study were to compare immunization with recombinant allergens using the adjuvant aluminum hydroxide (Alum) alone or combined with monophosphoryl lipid A (MPLA) for development of a preventive immunization against IBH. Twelve healthy Icelandic horses were vaccinated intralymphatically three times with 10 μg each of four recombinant Culicoides nubeculosus allergens in Alum or in Alum/MPLA. Injection with allergens in both Alum and Alum/MPLA resulted in significant increase in specific IgG subclasses and IgA against all r-allergens with no significant differences between the adjuvant groups. The induced antibodies from both groups could block binding of allergen specific IgE from IBH affected horses to a similar extent. No IgE-mediated reactions were induced. Allergen-stimulated PBMC from Alum/MPLA horses but not from Alum only horses produced significantly more IFNγ and IL-10 than PBMC from non-vaccinated control horses. In conclusion, intralymphatic administration of small amounts of pure allergens in Alum/MPLA induces high IgG antibody levels and Th1/Treg immune response and is a promising approach for immunoprophylaxis and immunotherapy against IBH.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adjuvants; Horses; IgG subclasses; Immunotherapy; Insect bite hypersensitivity

Mesh:

Substances:

Year:  2016        PMID: 27032498     DOI: 10.1016/j.vetimm.2016.02.017

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  7 in total

Review 1.  Outstanding animal studies in allergy II. From atopic barrier and microbiome to allergen-specific immunotherapy.

Authors:  Erika Jensen-Jarolim; Isabella Pali-Schöll; Franziska Roth-Walter
Journal:  Curr Opin Allergy Clin Immunol       Date:  2017-06

2.  A Pilot Qualitative Investigation of Stakeholders' Experiences and Opinions of Equine Insect Bite Hypersensitivity in England.

Authors:  Hannah R Lomas; Philip A Robinson
Journal:  Vet Sci       Date:  2018-01-09

3.  Allergen-specific immunoglobulin E in sera of horses affected with insect bite hypersensitivity, severe equine asthma or both conditions.

Authors:  Maëva Verdon; Simone Lanz; Claudio Rhyner; Vinzenz Gerber; Eliane Marti
Journal:  J Vet Intern Med       Date:  2018-12-06       Impact factor: 3.333

Review 4.  Solid-in-oil nanodispersions for transdermal drug delivery systems.

Authors:  Momoko Kitaoka; Rie Wakabayashi; Noriho Kamiya; Masahiro Goto
Journal:  Biotechnol J       Date:  2016-08-16       Impact factor: 4.677

Review 5.  Allergen-specific intralymphatic immunotherapy in human and animal studies.

Authors:  Seon Tae Kim; So Hyun Park; Sang Min Lee; Sang Pyo Lee
Journal:  Asia Pac Allergy       Date:  2017-07-19

6.  Cul o 2 specific IgG3/5 antibodies predicted Culicoides hypersensitivity in a group imported Icelandic horses.

Authors:  Fahad Raza; Renata Ivanek; Heather Freer; Dania Reiche; Horst Rose; Sigurbjörg Torsteinsdóttir; Vilhjálmur Svansson; Sigríður Björnsdóttir; Bettina Wagner
Journal:  BMC Vet Res       Date:  2020-08-10       Impact factor: 2.741

Review 7.  Formulations for Allergen Immunotherapy in Human and Veterinary Patients: New Candidates on the Horizon.

Authors:  Isabella Pali-Schöll; Douglas J DeBoer; Claudia Alessandri; Ahmed Adel Seida; Ralf S Mueller; Erika Jensen-Jarolim
Journal:  Front Immunol       Date:  2020-08-04       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.